Fosamax and Osteonecrosis of the Jaw: Evidence from Clinical Studies

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Assessment

The Immunodeficiency Foundation has long served as a curated repository for general health and scientific knowledge, with a particular emphasis on immunology and the historical evolution of medical understanding. Its archives have traditionally provided broad educational resources, covering foundational principles of human health, disease mechanisms, and therapeutic developments. This heritage of disseminating reliable, context-rich information has established a framework for examining how scientific inquiry progresses from general biological concepts to specific clinical observations. Within this tradition, the transition from broad health education to focused risk assessment follows a logical trajectory. As public health awareness has matured, the need to address specific exposure-related concerns has become increasingly apparent. One such area involves the long-term use of certain pharmaceutical agents and their potential associations with adverse outcomes. In particular, the bisphosphonate class of medications, widely prescribed for bone density management, has prompted scrutiny regarding rare but serious complications. This pivot from general health information to a more targeted occupational and clinical concern is exemplified by the inquiry into Fosamax exposure and the risk of osteonecrosis of the jaw. The question now shifts from broad educational context to a focused examination of what existing studies reveal about this specific association, moving the discussion toward evidence-based risk characterization without delving into mechanistic speculation.

Fosamax: Mechanism and Recognized Adverse Effects

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. Clinical presentation of ONJ typically involves delayed healing after dental procedures, such as tooth extraction, or spontaneous bone exposure, often accompanied by local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with the condition generally associated with invasive dental procedures, local infection, or both (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Duration of Exposure

The mechanistic pathways linking Fosamax to ONJ involve the drug's antiresorptive action on bone. Bisphosphonates inhibit osteoclast activity, reducing bone turnover. In the jawbone, which has high remodeling rates, this suppression can impair healing after minor trauma or infection. A multiscale characterization of jawbone provides comprehensive information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique structure and physiology of the jawbone may make it particularly susceptible to the effects of bisphosphonate therapy. Regarding the timeline between exposure and documented harm, the time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates a clear dose-response relationship in terms of duration of use.

Evidence for Causation and Adequacy of Warnings

Causation considerations for affected patients require careful evaluation. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as bone pain were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as symptoms improve upon withdrawal and recur upon re-exposure. Adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's labeling. The warnings and precautions section explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that known risk factors include invasive dental procedures, cancer, concomitant therapies, poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling also notes that the risk of ONJ may increase with duration of exposure and that discontinuation of bisphosphonate treatment may reduce the risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the labeling advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These warnings provide guidance for clinicians and patients, though the absolute risk remains low.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the relationship between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can increase the risk of osteonecrosis of the jaw (ONJ), a rare condition where jawbone tissue dies and becomes exposed. The risk is higher with longer duration of use, and the condition often occurs after dental procedures or infections. Studies show a dose-response relationship, with risk increasing after 2-3 years of treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How long does it take for Fosamax to cause jaw problems?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer exposure, with a threefold higher risk after 2-3 years and eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.